Actuate TherapeuticsACTU
13F holders, Q4 2024 (December 31)19holders +9
12new positions
4sold out
$7.96avg. 13F price*
At the end of Q4 2024, 19 institutions reported holding Actuate Therapeutics Inc. (ACTU) in their 13F filings, up 9 from Q3 2024. 12 opened new positions and 4 sold out. The largest holders were BIOS Capital Management, LP ($78.8M), Voss Capital, LP ($440K) and Geode Capital Management, LLC ($222K).
- Company
- Actuate Therapeutics Inc.
- CUSIP
- 005083100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 12 | $1.2M |
| Exits | 4 | $2.0M |
All 13F filers, Q3 2024 → Q4 2024: 154,487 shares bought and 314,169 shares sold, net −159,682 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 19 holders
| BIOS Capital Management, LP | 83.69% | — | 9,893,651 | $78.8M |
| Voss Capital, LP | 0.03% | New | 55,246 | $440K |
| Geode Capital Management, LLC | 0.00% | No change | 27,893 | $222K |
| Northwestern University | 0.35% | No change | 27,778 | $221K |
| Mercer Global Advisors Inc. | 0.00% | New | 16,344 | $130K |
| Sigma Planning Corp | 0.00% | New | 16,075 | $128K |
| Vanguard Group Inc. | 0.00% | New | 14,296 | $114K |
| KG Capital Management | 0.03% | No change | 12,000 | $96K |
| Goldman Sachs Group Inc. | 0.00% | New | 11,253 | $90K |
| OMERS ADMINISTRATION Corp | 0.00% | New | 10,583 | $84K |
| Envestnet Asset Management Inc. | 0.00% | New | 10,465 | $83K |
| Freestone Capital Holdings, LLC | 0.00% | New | 10,000 | $80K |
| BlackRock, Inc. | 0.00% | New | 7,745 | $62K |
| UBS Group AG | 0.00% | New | 1,934 | $15K |
| Morgan Stanley | 0.00% | New | 542 | $4K |
| Royal Bank of Canada | 0.00% | Reduce -99.1% | 302 | $2K |
| Bank of America Corp. | 0.00% | Add +4.3% | 24 | $191 |
| JPMorgan Chase & Co. | 0.00% | New | 3 | $24 |
| Citigroup Inc. | 0.00% | Reduce -100.0% | 2 | $16 |
"% of holder's portfolio" is ACTU's weight in each manager's 13F, not the share of Actuate Therapeutics Inc. the manager owns.